[Alpha Biz= Reporter Kim Sangjin] Lotte Biologics, a Contract Development and Manufacturing Organization (CDMO) in the biopharmaceutical industry, has decided on a capital increase of approximately 150 billion won.
This capital increase is aimed at raising funds for the construction of the first factory at the domestic Songdo Bio Campus. Lotte Holdings (004990), a subsidiary, will participate in the capital increase, with a price per share of 65,000 won.
Following this investment, Lotte Holdings' ownership stake in Lotte Biologics will remain at 80%, unchanged from before.
Lotte Biologics stated, "Through this issuance of new shares to existing shareholders, Lotte Holdings, among them, will finalize its participation in this capital increase after obtaining approval at the board of directors' meeting."
AlphaBIZ Kim SangJin(letyou@alphabiz.co.kr)
